Y111 (PD-L1 x CD3), a both PD-L1- and CD3-targeting bispecific antibody, that redirected T cells to attack PD-L1-expressing cancer cells, was designed under the Y-body® platform (25, 26). This evidence concerns the gene CD274 and cancer.